Validated methods for assessment of subclinical atherosclerosis in rheumatology

Nature Reviews Rheumatology

Volumn 8, Issue 4, 2012, Pages 224-234

  Kerekes, György ^a   Soltész, Pál ^a   Nurmohamed, Michael T ^b   Gonzalez Gay, Miguel A ^c   Turiel, Maurizio ^d   Végh, Edit ^a   Shoenfeld, Yehuda ^e   McInnes, Iain ^f   Szekanecz, Zoltán ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^d UNIVERSITY OF MILAN   (Italy)

^e SHEBA MEDICAL CENTER   (Israel)

^f UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANKLE BRACHIAL INDEX; ARTERIAL STIFFNESS; ARTERIAL WALL THICKNESS; ATHEROSCLEROSIS; AUGMENTATION INDEX; BRACHIAL ARTERY FLOW MEDIATED VASODILATATION; CARDIOVASCULAR PARAMETERS; CARDIOVASCULAR RISK; CAROTID ATHEROSCLEROSIS; COMPUTER ASSISTED TOMOGRAPHY; CORONARY CALCIUM CONTENT; CORONARY FLOW RESERVE; DIAGNOSTIC APPROACH ROUTE; DIAGNOSTIC IMAGING; ENDOTHELIAL DYSFUNCTION; HUMAN; LASER DOPPLER FLOWMETRY; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; POSTOCCLUSIVE REACTIVE HYPEREMIA; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROVOCATION TEST; PULSE WAVE; REVIEW; RHEUMATIC DISEASE; RISK ASSESSMENT; SUBCLINICAL ATHEROSCLEROSIS; VALIDATION STUDY; VASODILATATION;

ATHEROSCLEROSIS; HUMANS; MAGNETIC RESONANCE IMAGING; POSITRON-EMISSION TOMOGRAPHY; REPRODUCIBILITY OF RESULTS; RHEUMATIC DISEASES; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84859439662     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2012.16     Document Type: Review

References (132)

1. Mancia, G. et al. 2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. J. Hypertens. 25, 1751-1762 (2007).
2. Greenland, P. et al. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 122, 2748-2764 (2010).
3. Magnus, P. & Beaglehole, R. The real contribution of the major risk factors to the coronary epidemics: time to end the "only-50%" myth. Arch. Intern. Med. 161, 2657-2660 (2001).
4. Beaglehole, R. & Magnus, P. The search for new risk factors for coronary heart disease: occupational therapy for epidemiologists? Int. J. Epidemiol. 31, 1117-1122 (2002).
5. Ross, R. The pathogenesis of atherosclerosis - an update. N. Engl. J. Med. 314, 488-500 (1986).
6. Libby, P. Inflammation in atherosclerosis. Nature 420, 868-874 (2002).
7. Shoenfeld, Y. et al. Accelerated atherosclerosis in autoimmune rheumatic diseases. Circulation 112, 3337-3347 (2005).
8. Esdaile, J. M. et al. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum. 44, 2331-2337 (2001).
9. Szekanecz, Z. et al. Accelerated atherosclerosis in rheumatoid arthritis. Ann. NY Acad. Sci. 1108, 349-358 (2007).
10. Nurmohamed, M. T. Cardiovascular risk in rheumatoid arthritis. Autoimmun. Rev. 8, 663-667 (2009).
11. Sitia, S. et al. Cardiovascular involvement in systemic autoimmune diseases. Autoimmun. Rev. 8, 281-286 (2009).
12. Kitas, G. D. & Gabriel, S. E. Cardiovascular disease in rheumatoid arthritis: state of the art and future perspectives. Ann. Rheum. Dis. 70, 8-14 (2011).
13. Peters, M. J. et al. Does rheumatoid arthritis equal diabetes mellitus as an independent risk factor for cardiovascular disease? A prospective study. Arthritis Rheum. 61, 1571-1579 (2009).
14. Peters, M. J. et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann. Rheum. Dis. 69, 325-331 (2010).
15. Stamatelopoulos, K. S. et al. Atherosclerosis in rheumatoid arthritis versus diabetes: a comparative study. Arterioscler. Thromb. Vasc. Biol. 29, 1702-1708 (2009).
16. Ikonomidis, I. et al. Aortic elastic properties and left ventricular diastolic function in patients with Adamantiades-Behcet's disease. J. Am. Coll. Cardiol. 43, 1075-1081 (2004).
17. Protogerou, A. D. et al. Reduced pressure wave reflections in patients with active clinical status of Adamantiades-Behcet disease. Hellenic J. Cardiol. 49, 408-414 (2008).
18. Ludmer, P. L. et al. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N. Engl. J. Med. 315, 1046-1051 (1986).
19. Lefroy, D. C., Crake, T., Uren, N. G., Davies, G. J. & Maseri, A. Effect of inhibition of nitric oxide synthesis on epicardial coronary artery caliber and coronary blood flow in humans. Circulation 88, 43-54 (1993).
20. Poredos, P. Endothelial dysfunction in the pathogenesis of atherosclerosis. Clin. Appl. Thromb. Hemost. 7, 276-280 (2001).
21. Vanhoutte, P. M., Shimokawa, H., Tang, E. H. & Feletou, M. Endothelial dysfunction and vascular disease. Acta Physiol. (Oxford) 196, 193-222 (2009).
22. Higashi, Y. et al. A noninvasive measurement of reactive hyperemia that can be used to assess resistance artery endothelial function in humans. Am. J. Cardiol. 87, 121-125, A9 (2001).
23. Cracowski, J. L., Minson, C. T., Salvat-Melis, M. & Halliwill, J. R. Methodological issues in the assessment of skin microvascular endothelial function in humans. Trends Pharmacol. Sci. 27, 503-508 (2006).
24. Kuvin, J. T. et al. Assessment of peripheral vascular endothelial function with finger arterial pulse wave amplitude. Am. Heart J. 146, 168-174 (2003).
25. Rubinshtein, R. et al. Assessment of endothelial function by non-invasive peripheral arterial tonometry predicts late cardiovascular adverse events. Eur. Heart J. 31, 1142-1148 (2010).
26. Celermajer, D. S. et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 340, 1111-1115 (1992).
27. Joannides, R. et al. Nitric oxide is responsible for flow-dependent dilatation of human peripheral conduit arteries in vivo. Circulation 91, 1314-1319 (1995).
28. Corretti, M. C. et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J. Am. Coll. Cardiol. 39, 257-265 (2002).
29. Charakida, M., Masi, S., Luscher, T. F., Kastelein, J. J. & Deanfield, J. E. Assessment of atherosclerosis: the role of flow-mediated dilatation. Eur. Heart J. 31, 2854-2861 (2010).
30. Anderson, T. J. et al. Close relation of endothelial function in the human coronary and peripheral circulations. J. Am. Coll. Cardiol. 26, 1235-1241 (1995).
31. Lekakis, J. et al. Methods for evaluating endothelial function: a position statement from the European Society of Cardiology Working Group on Peripheral Circulation. Eur. J. Cardiovasc. Prev. Rehabil. 18, 775-789 (2011).
32. Jarvisalo, M. J. et al. Elevated serum C-reactive protein levels and early arterial changes in healthy children. Arterioscler. Thromb. Vasc. Biol. 22, 1323-1328 (2002).
33. Celermajer, D. S., Sorensen, K. E., Bull, C., Robinson, J. & Deanfield, J. E. Endothelium-dependent dilation in the systemic arteries of asymptomatic subjects relates to coronary risk factors and their interaction. J. Am. Coll. Cardiol. 24, 1468-1474 (1994).
34. Halcox, J. P. et al. Endothelial function predicts progression of carotid intima-media thickness. Circulation 119, 1005-1012 (2009).
35. Yeboah, J., Burke, G. L., Crouse, J. R. & Herrington, D. M. Relationship between brachial flow-mediated dilation and carotid intima-media thickness in an elderly cohort: the Cardiovascular Health Study. Atherosclerosis 197, 840-845 (2008).
36. Yeboah, J., Crouse, J. R., Hsu, F. C., Burke, G. L. & Herrington, D. M. Brachial flow-mediated dilation predicts incident cardiovascular events in older adults: the Cardiovascular Health Study. Circulation 115, 2390-2397 (2007).
37. Shimbo, D. et al. The association between endothelial dysfunction and cardiovascular outcomes in a population-based multi-ethnic cohort. Atherosclerosis 192, 197-203 (2007).
38. Gokce, N. et al. Predictive value of noninvasively determined endothelial dysfunction for long-term cardiovascular events in patients with peripheral vascular disease. J. Am. Coll. Cardiol. 41, 1769-1775 (2003).
39. Schroeder, S. et al. Noninvasive determination of endothelium-mediated vasodilation as a screening test for coronary artery disease: pilot study to assess the predictive value in comparison with angina pectoris, exercise electrocardiography, and myocardial perfusion imaging. Am. Heart J. 138, 731-739 (1999).
40. Kerekes, G. et al. Endothelial dysfunction and atherosclerosis in rheumatoid arthritis: a multiparametric analysis using imaging techniques and laboratory markers of inflammation and autoimmunity. J. Rheumatol. 35, 398-406 (2008).
41. Gonzalez-Gay, M. A., Gonzalez-Juanatey, C. & Ollier, W. E. Endothelial dysfunction in rheumatoid arthritis: influence of HLA-DRB1 alleles. Autoimmun. Rev. 3, 301-304 (2004).
42. Gonzalez-Juanatey, C. et al. HLA-DRB1 status affects endothelial function in treated patients with rheumatoid arthritis. Am. J. Med. 114, 647-652 (2003).
43. Vaudo, G. et al. Endothelial dysfunction in young patients with rheumatoid arthritis and low disease activity. Ann. Rheum. Dis. 63, 31-35 (2004).
44. Kerekes, G. et al. Effects of adalimumab treatment on vascular disease associated with early rheumatoid arthritis. Isr. Med. Assoc. J. 13, 147-152 (2011).
45. Hannawi, S., Marwick, T. H. & Thomas, R. Inflammation predicts accelerated brachial arterial wall changes in patients with recent-onset rheumatoid arthritis. Arthritis Res. Ther. 11, R51 (2009).
46. Sari, I. et al. Impaired endothelial function in patients with ankylosing spondylitis. Rheumatology (Oxford) 45, 283-286 (2006).
47. Bodnar, N. et al. Assessment of subclinical vascular disease associated with ankylosing spondylitis. J. Rheumatol. 38, 723-729 (2011).
48. Gonzalez-Juanatey, C. et al. Endothelial dysfunction in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors. Arthritis Rheum. 57, 287-293 (2007).
49. Kerekes, G. et al. Effects of biologics on vascular function and atherosclerosis associated with rheumatoid arthritis. Ann. NY Acad. Sci. 1173, 814-821 (2009).
50. Szekanecz, Z., Kerekes, G. & Soltesz, P. Vascular effects of biologic agents in RA and spondyloarthropathies. Nat. Rev. Rheumatol. 5, 677-684 (2009).
51. Hurlimann, D. et al. Anti-tumor necrosis factor-alpha treatment improves endothelial function in patients with rheumatoid arthritis. Circulation 106, 2184-2187 (2002).
52. Gonzalez-Juanatey, C. et al. Short-term adalimumab therapy improves endo-thelial function in patients with rheumatoid arthritis refractory to infliximab. Clin. Exp. Rheumatol. 24, 309-312 (2006).
53. Bilsborough, W. et al. Anti-tumour necrosis factor-alpha therapy over conventional therapy improves endothelial function in adults with rheumatoid arthritis. Rheumatol. Int. 26, 1125-1131 (2006).
54. Sidiropoulos, P. I. et al. Sustained improvement of vascular endothelial function during anti- TNFalpha treatment in rheumatoid arthritis patients. Scand. J. Rheumatol. 38, 6-10 (2009).
55. van Eijk, I. C. et al. Microvascular function is impaired in ankylosing spondylitis and improves after tumour necrosis factor alpha blockade. Ann. Rheum. Dis. 68, 362-366 (2009).
56. Gonzalez-Juanatey, C. et al. Active but transient improvement of endothelial function in rheumatoid arthritis patients undergoing long-term treatment with anti-tumor necrosis factor alpha antibody. Arthritis Rheum. 51, 447-450 (2004).
57. Gonzalez-Juanatey, C. et al. Short-term improvement of endothelial function in rituximab-treated rheumatoid arthritis patients refractory to tumor necrosis factor alpha blocker therapy. Arthritis Rheum. 59, 1821-1824 (2008).
58. Kerekes, G. et al. Effects of rituximab treatment on endothelial dysfunction, carotid atherosclerosis, and lipid profile in rheumatoid arthritis. Clin. Rheumatol. 28, 705-710 (2009).
59. Turner, J., Belch, J. J. & Khan, F. Current concepts in assessment of microvascular endothelial function using laser Doppler imaging and iontophoresis. Trends Cardiovasc. Med. 18, 109-116 (2008).
60. Datta, D., Ferrell, W. R., Sturrock, R. D., Jadhav, S. T. & Sattar, N. Inflammatory suppression rapidly attenuates microvascular dysfunction in rheumatoid arthritis. Atherosclerosis 192, 391-395 (2007).
61. Galarraga, B., Khan, F., Kumar, P., Pullar, T. & Belch, J. J. C-reactive protein: the underlying cause of microvascular dysfunction in rheumatoid arthritis. Rheumatology (Oxford) 47, 1780-1784 (2008).
62. van Eijk, I. C., Serne, E. H., Dijkmans, B. A., Smulders, Y. & Nurmohamed, M. Microvascular function is preserved in newly diagnosed rheumatoid arthritis and low systemic inflammatory activity. Clin. Rheumatol. 30, 1113-1118 (2011).
63. Turiel, M. et al. Non-invasive assessment of coronary flow reserve and ADMA levels: a case-control study of early rheumatoid arthritis patients. Rheumatology (Oxford) 48, 834-839 (2009).
64. Vesely, M. R. & Dilsizian, V. Microvascular angina: assessment of coronary blood flow, flow reserve, and metabolism. Curr. Cardiol. Rep. 13, 151-158 (2011).
65. Gullu, H. et al. Interrelationship between noninvasive predictors of atherosclerosis: transthoracic coronary flow reserve, flow-mediated dilation, carotid intima-media thickness, aortic stiffness, aortic distensibility, elastic modulus, and brachial artery diameter. Echocardiography 23, 835-842 (2006).
66. Atzeni, F. et al. Preclinical impairment of coronary flow reserve in patients with rheumatoid arthritis. Ann. NY Acad. Sci. 1108, 392-397 (2007).
67. Caliskan, M. et al. Impaired coronary microvascular function in familial Mediterranean fever. Atherosclerosis 195, e161-e167 (2007).
68. Turiel, M. et al. Effects of long-term disease-modifying antirheumatic drugs on endothelial function in patients with early rheumatoid arthritis. Cardiovasc. Ther. 28, e53-e64 (2010).
69. Ikonomidis, I. et al. Inhibition of interleukin-1 by anakinra improves vascular and left ventricular function in patients with rheumatoid arthritis. Circulation 117, 2662-2669 (2008).
70. Laurent, S. et al. Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur. Heart J. 27, 2588-2605 (2006).
71. London, G. M. & Pannier, B. Arterial functions: how to interpret the complex physiology. Nephrol. Dial. Transplant. 25, 3815-3823 (2010).
72. Nichols, W. W. Clinical measurement of arterial stiffness obtained from noninvasive pressure waveforms. Am. J. Hypertens. 18, 3S-10S (2005).
73. Williams, B. et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 113, 1213-1225 (2006).
74. Soltesz, P. et al. A comparative study of arterial stiffness, flow-mediated vasodilation of the brachial artery, and the thickness of the carotid artery intima-media in patients with systemic autoimmune diseases. Clin. Rheumatol. 28, 655-662 (2009).
75. Wilkinson, I. B. et al. Pulse-wave analysis: clinical evaluation of a noninvasive, widely applicable method for assessing endothelial function. Arterioscler. Thromb. Vasc. Biol. 22, 147-152 (2002).
76. O'Rourke, M. Mechanical principles in arterial disease. Hypertension 26, 2-9 (1995).
77. Podolec, P. et al. Aortic pulse wave velocity and carotid-femoral pulse wave velocity: similarities and discrepancies. Hypertens. Res. 30, 1151-1158 (2007).
78. Blacher, J., Asmar, R., Djane, S., London, G. M. & Safar, M. E. Aortic pulse wave velocity as a marker of cardiovascular risk in hypertensive patients. Hypertension 33, 1111-1117 (1999).
79. Lebrun, C. E. et al. Arterial stiffness in postmenopausal women: determinants of pulse wave velocity. J. Hypertens. 20, 2165-2172 (2002).
80. Salvi, P. et al. Validation of a new non-invasive portable tonometer for determining arterial pressure wave and pulse wave velocity: the PulsePen device. J. Hypertens. 22, 2285-2293 (2004).
81. Weber, T. et al. Noninvasive determination of carotid-femoral pulse wave velocity depends critically on assessment of travel distance: a comparison with invasive measurement. J. Hypertens. 27, 1624-1630 (2009).
82. Reference Values for Arterial Stiffness' Collaboration. Determinants of pulse wave velocity in healthy people and in the presence of cardiovascular risk factors: 'establishing normal and reference values'. Eur. Heart J. 31, 2338-2350 (2010).
83. Mitchell, G. F. et al. Arterial stiffness and cardiovascular events: the Framingham Heart Study. Circulation 121, 505-511 (2010).
84. Baulmann, J. et al. A new oscillometric method for assessment of arterial stiffness: comparison with tonometric and piezo-electronic methods. J. Hypertens. 26, 523-528 (2008).
85. Horvath, I. G. et al. Invasive validation of a new oscillometric device (Arteriograph) for measuring augmentation index, central blood pressure and aortic pulse wave velocity. J. Hypertens. 28, 2068-2075 (2010).
86. Pieringer, H., Stuby, U., Pohanka, E. & Biesenbach, G. Arterial stiffness in a muscular artery in women with longstanding rheumatoid arthritis compared with healthy controls and patients with traditional cardiovascular risk factors. Rheumatol. Int. 30, 1335-1339 (2010).
87. Maki-Petaja, K. M. et al. Rheumatoid arthritis is associated with increased aortic pulse-wave velocity, which is reduced by anti-tumor necrosis factor-alpha therapy. Circulation 114, 1185-1192 (2006).
88. Holmes, M. V. et al. Paradoxical association of C-reactive protein with endothelial function in rheumatoid arthritis. PLoS ONE 5, e10242 (2010).
89. Avalos, I. et al. Increased augmentation index in rheumatoid arthritis and its relationship to coronary artery atherosclerosis. J. Rheumatol. 34, 2388-2394 (2007).
90. Cypiene, A. et al. Non-invasive assessment of arterial stiffness indices by applanation tonometry and pulse wave analysis in patients with rheumatoid arthritis treated with TNF-alpha blocker remicade (infliximab). Proc. West. Pharmacol. Soc. 50, 119-122 (2007).
91. Provan, S. A. et al. Early prediction of increased arterial stiffness in patients with chronic inflammation: a 15-year followup study of 108 patients with rheumatoid arthritis. J. Rheumatol. 38, 606-612 (2011).
92. Timar, O. et al. Increased arterial stiffness as the marker of vascular involvement in systemic sclerosis. J. Rheumatol. 35, 1329-1333 (2008).
93. Wong, M. et al. Infliximab improves vascular stiffness in patients with rheumatoid arthritis. Ann. Rheum. Dis. 68, 1277-1284 (2009).
94. Angel, K. et al. Tumor necrosis factor-alpha antagonists improve aortic stiffness in patients with inflammatory arthropathies: a controlled study. Hypertension 55, 333-338.
95. Pignoli, P., Tremoli, E., Poli, A., Oreste, P. & Paoletti, R. Intimal plus medial thickness of the arterial wall: a direct measurement with ultrasound imaging. Circulation 74, 1399-1406 (1986).
96. Virmani, R. et al. Effect of aging on aortic morphology in populations with high and low prevalence of hypertension and atherosclerosis. Comparison between occidental and Chinese communities. Am. J. Pathol. 139, 1119-1129 (1991).
97. Bots, M. L., Hofman, A. & Grobbee, D. E. Increased common carotid intima-media thickness. Adaptive response or a reflection of atherosclerosis? Findings from the Rotterdam Study. Stroke 28, 2442-2447 (1997).
98. Bots, M. L., Hofman, A., De Jong, P. T. & Grobbee, D. E. Common carotid intima-media thickness as an indicator of atherosclerosis at other sites of the carotid artery. The Rotterdam Study. Ann. Epidemiol. 6, 147-153 (1996).
99. Simon, A., Chironi, G. & Levenson, J. Comparative performance of subclinical atherosclerosis tests in predicting coronary heart disease in asymptomatic individuals. Eur. Heart J. 28, 2967-2971 (2007).
100. Nambi, V. et al. Common carotid artery intima-media thickness is as good as carotid intima-media thickness of all carotid artery segments in improving prediction of coronary heart disease risk in the Atherosclerosis Risk in Communities (ARIC) study. Eur. Heart J. http://dx.doi.org/ 10.1093/eurheartj/ ehr192.
101. Stein, J. H. et al. Use of carotid ultrasound to identify subclinical vascular disease and evaluate cardiovascular disease risk: a consensus statement from the American Society of Echocardiography Carotid Intima-Media Thickness Task Force. Endorsed by the Society for Vascular Medicine. J. Am. Soc. Echocardiogr. 21, 93-111 (2008).
102. Spence, J. D. et al. Carotid plaque area: a tool for targeting and evaluating vascular preventive therapy. Stroke 33, 2916-2922 (2002).
103. Nambi, V. et al. Carotid intima-media thickness and presence or absence of plaque improves prediction of coronary heart disease risk: the ARIC (Atherosclerosis Risk In Communities) study. J. Am. Coll. Cardiol. 55, 1600-1607 (2010).
104. Kramer, H. R. & Giles, J. T. Cardiovascular disease risk in rheumatoid arthritis: progress, debate, and opportunity. Arthritis Care Res. (Hoboken) 63, 484-499 (2011).
105. Daza, L., Aguirre, M., Jimenez, M., Herrera, R. & Bollain, J. J. Common carotid intima-media thickness and von Willebrand factor serum levels in rheumatoid arthritis female patients without cardiovascular risk factors. Clin. Rheumatol. 26, 533-537 (2007).
106. Del Rincon, I. et al. Association between carotid atherosclerosis and markers of inflammation in rheumatoid arthritis patients and healthy subjects. Arthritis Rheum. 48, 1833-1840 (2003).
107. Gerli, R. et al. Precocious atherosclerosis in rheumatoid arthritis: role of traditional and disease-related cardiovascular risk factors. Ann. NY Acad. Sci. 1108, 372-381 (2007).
108. Gonzalez-Juanatey, C. et al. Increased prevalence of severe subclinical atherosclerotic findings in long-term treated rheumatoid arthritis patients without clinically evident atherosclerotic disease. Medicine (Baltimore) 82, 407-413 (2003).
109. Hannawi, S., Haluska, B., Marwick, T. H. & Thomas, R. Atherosclerotic disease is increased in recent-onset rheumatoid arthritis: a critical role for inflammation. Arthritis Res. Ther. 9, R116 (2007).
110. Peters, M. J. et al. Relations between autoantibodies against oxidized low-density lipoprotein, inflammation, subclinical atherosclerosis, and cardiovascular disease in rheumatoid arthritis. J. Rheumatol. 35, 1495-1499 (2008).
111. Gonzalez-Gay, M. A., Gonzalez-Juanatey, C., Vazquez-Rodriguez, T. R., Martin, J. & Llorca, J. Endothelial dysfunction, carotid intima-media thickness, and accelerated atherosclerosis in rheumatoid arthritis. Semin. Arthritis Rheum. 38, 67-70 (2008).
112. Gonzalez-Juanatey, C. et al. The high prevalence of subclinical atherosclerosis in patients with ankylosing spondylitis without clinically evident cardiovascular disease. Medicine (Baltimore) 88, 358-365 (2009).
113. Peters, M. J. et al. Signs of accelerated preclinical atherosclerosis in patients with ankylosing spondylitis. J. Rheumatol. 37, 161-166 (2009).
114. Szucs, G. et al. Endothelial dysfunction precedes atherosclerosis in systemic sclerosis - relevance for prevention of vascular complications. Rheumatology (Oxford) 46, 759-762 (2007).
115. Gonzalez-Juanatey, C. et al. High prevalence of subclinical atherosclerosis in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors. Arthritis Rheum. 57, 1074-1080 (2007).
116. Salmon, J. E. & Roman, M. J. Subclinical atherosclerosis in rheumatoid arthritis and systemic lupus erythematosus. Am. J. Med. 121, S3-S8 (2008).
117. Gonzalez-Juanatey, C., Llorca, J., Garcia-Porrua, C., Martin, J. & Gonzalez-Gay, M. A. Effect of anti-tumor necrosis factor alpha therapy on the progression of subclinical atherosclerosis in severe rheumatoid arthritis. Arthritis Rheum. 55, 150-153 (2006).
118. Gonzalez-Juanatey, C., Llorca, J., Martin, J. & Gonzalez-Gay, M. A. Carotid intima-media thickness predicts the development of cardiovascular events in patients with rheumatoid arthritis. Semin. Arthritis Rheum. 38, 366-371 (2009).
119. Polonsky, T. S. et al. Coronary artery calcium score and risk classification for coronary heart disease prediction. JAMA 303, 1610-1616 (2010).
120. Budoff, M. J. & Gul, K. M. Expert review on coronary calcium. Vasc. Health Risk Manag. 4, 315-324 (2008).
121. Chung, C. P. et al. Increased coronary-artery atherosclerosis in rheumatoid arthritis: relationship to disease duration and cardiovascular risk factors. Arthritis Rheum. 52, 3045-3053 (2005).
122. Giles, J. T. et al. Coronary arterial calcification in rheumatoid arthritis: comparison with the Multi-Ethnic Study of Atherosclerosis. Arthritis Res. Ther. 11, R36 (2009).
123. Kao, A. H. et al. Subclinical coronary artery calcification and relationship to disease duration in women with rheumatoid arthritis. J. Rheumatol. 35, 61-69 (2008).
124. Asanuma, Y. et al. Premature coronary-artery atherosclerosis in systemic lupus erythematosus. N. Engl. J. Med. 349, 2407-2415 (2003).
125. Diehm, C. et al. High prevalence of peripheral arterial disease and co-morbidity in 6880 primary care patients: cross-sectional study. Atherosclerosis 172, 95-105 (2004).
126. Murabito, J. M. et al. Prevalence and clinical correlates of peripheral arterial disease in the Framingham Offspring Study. Am. Heart J. 143, 961-965 (2002).
127. Khan, T. H., Farooqui, F. A. & Niazi, K. Critical review of the ankle brachial index. Curr. Cardiol. Rev. 4, 101-106 (2008).
128. Fowkes, F. G. et al. Ankle brachial index combined with Framingham Risk Score to predict cardiovascular events and mortality: a meta-analysis. JAMA 300, 197-208 (2008).
129. Alkaabi, J. K., Ho, M., Levison, R., Pullar, T. & Belch, J. J. Rheumatoid arthritis and macrovascular disease. Rheumatology (Oxford) 42, 292-297 (2003).
130. del Rincon, I., Haas, R. W., Pogosian, S. & Escalante, A. Lower limb arterial incompressibility and obstruction in rheumatoid arthritis. Ann. Rheum. Dis. 64, 425-432 (2005).
131. Stamatelopoulos, K. S. et al. Subclinical peripheral arterial disease in rheumatoid arthritis. Atherosclerosis 212, 305-309 (2010).
132. Ikonomidis, I., Stamatelopoulos, K., Lekakis, J., Vamvakou, G. D. & Kremastinos, D. T. Inflammatory and non-invasive vascular markers: the multimarker approach for risk stratification in coronary artery disease. Atherosclerosis 199, 3-11 (2008).